Saturday, May 23, 2026
ISSN 2765-8767
  • Home
  • Courses
  • About Us
  • Contact us
  • Support Us
  • Home
  • Courses
  • About Us
  • Contact us
  • Support Us

From patient to patient-advocate, the story of Jaime Sanchez

Jaime Sanchez has worn many hats throughout her life, but her favorite role is being a mother. She has a diverse background, having studied and worked in fields like nursing, physical therapy, criminal justice, and early elementary teacher education, as well as home-business ownership, management, waitressing, and human resources, not in chronological order.

Jaime is a volunteer hostess and graphic assistant of the show “DocToks with Dr. Forest Tennant and Friends”, offering her help in the pain and addiction communities. She dreams of the day these communities unite to stand together. She hopes all people will recognize that anyone could face similar challenges, especially due to an accident, injury, or unexpected illness.

She recently wrote an article for Daily Remedy, Pain Upon Pain.

#Forest #Tennant #chronic #pain #patient #advocacy

Daily Remedy

Daily Remedy

Dr. Jay K Joshi serves as the editor-in-chief of Daily Remedy. He is a serial entrepreneur and sought after thought-leader for matters related to healthcare innovation and medical jurisprudence. He has published articles on a variety of healthcare topics in both peer-reviewed journals and trade publications. His legal writings include amicus curiae briefs prepared for prominent federal healthcare cases.

Leave a Reply

Your email address will not be published. Required fields are marked *

Videos

Policy Shift in Peptide Regulation

FDA Evaluation of Certain Bulk Drug Substances in Compounding: Clinical Interpretation

FDA Evaluation of Certain Bulk Drug Substances in Compounding: Clinical Interpretation

Clinicians increasingly encounter patients using or requesting peptide-based therapies sourced through compounding pharmacies. The U.S. Food and Drug Administration has identified a subset of bulk drug substances, including certain peptides, that may present significant safety risks when used in compounded formulations. The clinical question is whether these regulatory signals reflect meaningful patient-level risk and how they should influence prescribing behavior. This matters because compounded peptides often sit outside traditional approval pathways, creating uncertainty around quality, dosing consistency, and safety. Understanding...

Read more

Join Our Newsletter!